For example, previous work on transgenic AD models demonstrated that high-dose sodium selenate significantly impacts tau aggregation by upregulating PP2A/PR55, thereby dephosphorylating tau and reducing p-tau and t-tau levels in the hippocampus and amygdala (Corcoran et al., 2010), and reversed spatial learning, memory, and motor deficits (Corcoran et al., 2010; van Eersel et al., 2010). This evidence concerns the gene MAPT and Alzheimer disease.